Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
Kurth KH, Bouffioux C, Sylvester R, de Pauw M. Kurth KH, et al. Prog Clin Biol Res. 1988;269:525-37. Prog Clin Biol Res. 1988. PMID: 3134663 Clinical Trial. No abstract available.
Long-term follow-up in superficial transitional cell carcinoma of the bladder: prognostic factors for time to first recurrence, recurrence rate, and survival. Final results of a randomized trial comparing doxorubicin hydrochloride, ethoglucid, and transurethral resection alone. EORTC Genitourinary Tract Cancer Cooperative Group.
Kurth K, Schroeder FH, Debruyne F, Senge T, Pavone-Macaluso M, de Pauw M, ten Kate F, Sylvester R. Kurth K, et al. Prog Clin Biol Res. 1989;303:481-90. Prog Clin Biol Res. 1989. PMID: 2675005 Clinical Trial. No abstract available.
Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
Kurth K, Tunn U, Ay R, Schröder FH, Pavone-Macaluso M, Debruyne F, ten Kate F, de Pauw M, Sylvester R. Kurth K, et al. J Urol. 1997 Aug;158(2):378-84. doi: 10.1016/s0022-5347(01)64484-7. J Urol. 1997. PMID: 9224307 Clinical Trial.
Response criteria for phase III studies of superficial bladder cancer.
Schröder FH, Sylvester R, Gustafson H, Kawai T, Kurth KH, Matsuda M, Miyakawa M, Newling DW, Studer E. Schröder FH, et al. Among authors: kurth kh. Prog Clin Biol Res. 1986;221:311-21. Prog Clin Biol Res. 1986. PMID: 3543946 Clinical Trial. No abstract available.
Prognostic factors in superficial bladder cancer.
Aso Y, Anderson L, Soloway M, Bouffioux C, Chisholm G, Debruyne F, Kawai T, Kurth KH, Maru A, Straffon WG. Aso Y, et al. Among authors: kurth kh. Prog Clin Biol Res. 1986;221:257-69. Prog Clin Biol Res. 1986. PMID: 3809183 No abstract available.
167 results